INTRODUCTION
Cystic fibrosis (CF) is one of the most prevalent severe genetic diseases, with a high economic impact on healthcare systems due to its complexity [1] . The results of literature reviews, surveys, and registry analyses show a mean prevalence of 0.737/10,000 citizens in the 27 EU countries [2] . This prevalence is similar to the value of 0.680/10,000 citizens in Italy [3] .
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CF is caused by a lack or dysfunction of cystic fibrosis transmembrane regulator (CFTR) protein, which acts mainly as a chloride channel at the apical membrane of epithelial cells, with consequent alteration of electrolyte transport, production of abnormally thick secretions, and progressive organ damage [4] . The clinical picture of CF is highly variable in terms of organ involvement (sweat glands, airways, pancreas, liver, gut, deferent ducts), age at diagnosis, and development of complications [5] . Lung disease is observed in over 90% of patients and represents the leading cause of morbidity and mortality [6] .
Since its first description in 1938, CF has progressively evolved from a disease leading to death at a very young age due to respiratory failure and malnutrition, to a chronic condition with different manifestations also affecting adults [7] .
Over the last 20 years, the therapeutic approach has markedly improved with the availability of new therapies for the prevention and treatment of respiratory infections (mucus active drugs, antibiotics) and closer attention to nutritional status and to complications associated with the disease (e.g., diabetes, liver disease, osteoporosis). While in the past antibiotics were mostly used to treat the exacerbations of CF-associated lung disease. More recently, the chronic use of antibiotics administered in aerosol formulation to suppress lung infection has become common practice in the routine care of CF and is strongly recommended by current CF therapeutic guidelines [8, 9] .
The marked improvement in the therapeutic approach for CF has been paralleled by a progressive increase in mean life expectancy, which is now nearly 40 years in Western countries [10] , with a consequential increase in the number of adult patients [11] who often have a more complex and severe form of the disease.
Advances in therapy have been incremental and have resulted in an increase in direct medical costs and treatment burden [12] .
Several studies designed to assess the costs of illness in patients with CF were carried out more than two decades ago [13] [14] [15] [16] [17] [18] [19] [20] [21] . These studies were reviewed by Krauth et al. [1] who highlighted the wide range of mean annual cost per patient (US $6,200-16,300, 1996 rate), mainly due to differences in the clinical conditions of the patients considered, healthcare systems involved, and in the completeness of healthcare services and resource consumed.
Healthcare costs were directly related to age and severity of the disease [1] . Most of these studies had major limitations, including the fact that only five were based on individual patient care data [14, 16, [18] [19] [20] , whereas three were only aggregated expert cost estimations.
More recently, Briesacher et al. [22] examined patterns of treatment in relation to whole costs using a nationwide research to US$31,722) and for older patients, which more than doubled over the same period.
As no study has been conducted in Italy, the aim of this economic evaluation was to estimate the mean annual costs associated with the treatment of CF patients for the Italian National Healthcare Service (NHS). The authors therefore conducted a prospective, monocentric study to assess direct medical costs associated with CF treatment in Italy. All other costs (e.g., productivity losses, informal care, out-of-pocket expenses, etc) were not considered.
MATERIALS AND METHODS

Study Design
The authors carried out an observational, prospective, monocentric, prevalence-based study with a bottom-up design (consumption/ cost data of individual patients were determined and costs were aggregated over groups to arrive at total disease costs) [23] . values: mild (FEV 1 ≥70% of predicted), moderate (FEV 1 ≥ 40-<70%) and severe (FEV 1 <40%) [9] .
In addition, the probability of 5-year survival was calculated for each patient in Group 2, according to the model proposed by Liou et al. [24, 25] . 
Annual Cost Analysis
The mean annual treatment cost was based on A mean single annual cost was calculated for patients in Group 1. For patients in Group 2, three mean annual costs were calculated according to the lung disease severity class; a single mean annual cost was also estimated, adjusted for the actual distribution of the total number of patients followed-up at the CFRRC in each class of disease severity.
Statistical Analysis
Continuous data were expressed as means ± standard deviations or medians with ranges according to the distribution of the variables.
Categorical data were expressed as numbers and percentages. The significance of the differences between groups was evaluated by the Mann- 
RESULTS
Patient Demographics and Disease Severity at Enrollment
A total of 161 CF patients were enrolled; 55 consecutive patients aged ≤5 years In Group 2, a positive correlation between age and lung disease severity was documented (Fig. 1) . Table 2 shows the distribution of patients in Group 2 by disease severity and the corresponding probability of 5-year survival that were inversely correlated. The difference in the probability of survival across severity groups was statistically significant (P < 0.001). Table 3) .
Mean days on treatment/year/patient for different drug categories are shown in Table 3 .
Of note, the number of days on antibiotic treatment (by any route of administration) increased significantly with age and lung disease severity (P < 0.001). in Group 2 with severe disease (Table 4 ). This increase in costs involved all items. The relative contribution of hospitalizations on the overall costs increased with severity of lung disease (Fig. 2 ). All differences in cost, between the two age groups and the subgroups with different disease severities, were statistically significant, with the only exception of costs related to devices, which was not significant (Table 4) . Since patients with severe lung disease were more likely to be enrolled, due to a higher likelihood of access to the CFRRC compared with those with milder lung disease, we estimated a single mean annual cost for Group 2, adjusting for the actual distribution of all patients aged >5 years followed-up at the CRRFC (n = 338) in each class of disease severity.
Actually, the frequency of severe lung disease was higher among the 106 patients enrolled in Group 2 (12.3%) than in all patients aged >5 years followed at our center (8.6%). A mean annual cost per patient in Group 2 was estimated at €15,137, which is more than three times the cost for patients of Group 1 (€4,164, P < 0.0001
Finally, the mean annual cost for adult patients (≥18 years) was 1.7 times higher than the cost for patients aged 5-18 years (€20,931 ± €14,903 vs. €12,378 ± €11,277, P = 0.004 MannWhitney Test) and five times higher than for patients ≤5 years (€4,164 ± €4,065, P < 0.0001
Mann-Whitney Test). This system greatly favored a reliable monitoring of drug utilization in our study. The results also demonstrate a direct correlation between treatment cost and age;
the ratio between the mean cost of illness for adults and children was 3.4 in the current study, which is higher than previously reported (2.0-2.3) [14, 27] . It cannot be excluded that the lower economic resources spent for pediatric patients may be attributed to the aggressive therapeutic approach, which is now recommended beginning at the time of diagnosis and is associated with slower progression of lung disease and a reduced number of hospitalizations in childhood [28] .
Indeed, the cost for hospitalization was 17-fold higher in patients in Group 2 with severe lung disease compared with patients in Group 1.
The direct medical costs of illness estimated in the present study are slightly lower than those reported in two recent studies. In a multicenter study involving seven CF centers in Germany, Eidt-Koch et al. [29] 
